Shattuck Labs (NASDAQ:STTK) Given "Neutral" Rating at HC Wainwright

HC Wainwright restated their neutral rating on shares of Shattuck Labs (NASDAQ:STTK - Free Report) in a report issued on Thursday,Benzinga reports.

Several other equities research analysts also recently commented on STTK. Leerink Partnrs raised Shattuck Labs to a "strong-buy" rating in a report on Monday, March 17th. Leerink Partners initiated coverage on shares of Shattuck Labs in a research report on Monday, March 17th. They set an "outperform" rating and a $4.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Shattuck Labs currently has an average rating of "Moderate Buy" and a consensus price target of $7.50.

Shattuck Labs Stock Down 9.9 %

Shares of NASDAQ:STTK traded down $0.10 during midday trading on Thursday, reaching $0.95. The company's stock had a trading volume of 97,351 shares, compared to its average volume of 377,186. The firm has a 50 day moving average of $1.24 and a 200-day moving average of $1.46. The firm has a market capitalization of $45.36 million, a P/E ratio of -0.62 and a beta of 1.66. Shattuck Labs has a 12-month low of $0.94 and a 12-month high of $11.76.

Remove Ads

Shattuck Labs (NASDAQ:STTK - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.01. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. On average, research analysts predict that Shattuck Labs will post -1.48 EPS for the current year.

Hedge Funds Weigh In On Shattuck Labs

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Zacks Investment Management purchased a new position in shares of Shattuck Labs during the fourth quarter valued at approximately $25,000. Virtu Financial LLC bought a new stake in Shattuck Labs in the 4th quarter worth approximately $30,000. Atom Investors LP purchased a new stake in Shattuck Labs during the 3rd quarter valued at $35,000. Readystate Asset Management LP bought a new position in shares of Shattuck Labs during the 3rd quarter valued at $39,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Shattuck Labs in the 4th quarter worth $45,000. Institutional investors own 58.74% of the company's stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.